Abcuro
Healthcare Access & Wellbeing
Developing therapies for diseases through modulation of cytotoxic cells.
Impact Rating
Developing therapies for diseases through modulation of cytotoxic cells.
Company Overview
Abcuro aims to develop immune-modulatory bio-therapeutics for treating autoimmunity and cancer. They use systematic target validation and clinical insights to identify new targets. Their bioinformatics use and ex-vivo validation in diseased tissue have led to new approaches to target key immune system compartments.
Abcuro's Impact
Abcuro is committed to developing a new class of immune modulatory bio-therapeutics for treating autoimmunity and cancer.
Core Mission and Values
Abcuro is dedicated to developing innovative therapeutics for autoimmune diseases and cancer, with an experienced team of curious, analytical individuals committed to bringing meaningful advances to patients. Their goal is to make a significant difference in patient care.
Current Investors
Investors include Bain Capital Life Sciences, RA Capital Management, Redmile Group, Samsara BioCapital.
Leadership & Team
Alex Martin
CEO
Alex Martin, with over 30 years of experience in the biopharmaceutical industry, has held various positions including CEO of Palladio Biosciences, CEO of Realm Therapeutics, and CEO of BioXell. He holds an MBA from Harvard.
Karen Tubridy
Chief Development Officer
Karen Tubridy, with over 30 years of experience in drug development strategy and operations, has held senior positions at Verseau Therapeutics, Akebia Therapeutics, and Eleven Bio.
Steven A. Greenberg
Chief Scientific Officer
Steven A Greenberg, a clinical neurologist and Medical Professor, specialises in translational medicine. He has authored over 100 publications and served as Principal Investigator for clinical trials. Greenberg holds degrees in Mathematics, Medical Informatics, and Medicine.
H. Jeffrey Wilkins
Chief Medical Officer
Jeffrey Wilkin, a clinical leader with extensive experience in immunology and rare diseases, has led clinical development programs at various companies and pharmaceutical companies.
How are Abcuro using funds raised?
Abcuro plans to utilise the financing proceeds from Series B to conduct a Phase 2/3 clinical trial on ABC008, a monoclonal antibody targeting KLRG1 for the treatment of inclusion body myositis.
How are Abcuro driving innovation?
Abcuro is advancing ABC008, a first-in-class anti-KLRG1 antibody, into clinical studies to deplete cytotoxic T cells attacking healthy muscle tissue in inclusion body myositis patients. The company has received FDA orphan drug designation for ABC008 in IBM. ABC015, an anti-KLRG1 blocking antibody, is also being advanced.
Risks associated with Abcuro
Despite bioinformatics enhancing medical research and treatment methods, it also poses ethical concerns like data privacy and potential misuse of personal health information. Abcuro must understand these issues to make informed decisions and uphold ethical standards in their practice.
Research by: Bilal Ismail
Latest News in Life Sciences
07/11/25, 03:00 PM
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today - IDEXX Laboratories ( NASDAQ:IDXX )
IDEXX Laboratories IDXX has outperformed the market over the past 10 years by 12.19% on an annualized basis producing an average annual return of 23.57%. Currently, IDEXX Laboratories has a market capitalization of $43.85 billion.
Source: Benzinga
Read more →
07/11/25, 02:42 PM
Lowey Dannenberg Notifies UroGen Pharma Ltd. ( "UroGen" or the "Company" ) ( NASDQ: URGN ) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
NEW YORK, July 11, 2025 ( GLOBE NEWSWIRE ) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against UroGen Pharma Ltd. ( "UroGen" or the "Company" ) URGN for violations of the federal securities laws ...
Source: Benzinga
Read more →
07/11/25, 02:30 PM
NuCana Announces Plan to Implement ADS Ratio Change
EDINBURGH, United Kingdom, July 11, 2025 ( GLOBE NEWSWIRE ) -- NuCana plc ( NASDAQ: NCNA ) ( "NuCana" or the "Company" ) announced plans to change the ratio of its American Depository Shares ( "ADSs" ) to its ordinary shares from one ( 1 ) ADS, representing twenty-five ( 25 ) ordinary shares, to ...
Source: Business Insider
Read more →